Navigation Links
Taxus VI Clinical Trial Demonstrates Positive Long-Term Outcomes,for Moderate-Release Paclitaxel-Eluting Stent at Four Years

Trial results report no new stent thrombosis after two years in high-risk patient population

NATICK, Mass., and BARCELONA, Spain, May 22, 2007 /PRNewswire-FirstCall/ -- Boston Scientific Corporation today announced four-year follow-up data from its TAXUS VI clinical trial. The data demonstrated that the safety and efficacy benefits associated with a moderate-release formulation of the TAXUS(R) Express(TM) paclitaxel-eluting stent system -- which is not approved for commercial distribution -- were maintained at four years with no new stent thrombosis reported after two years. Analysis of the data was presented by Professor Eberhard Grube, M.D., Heart Center Siegburg, Germany, the Co- Principal Investigator of the trial. The Company made the announcement at the annual Paris Course on Revascularization (EuroPCR) in Barcelona.

"Even though the moderate-release TAXUS formulation, with an 8-10 fold higher in vitro dose, was never commercialized, the excellent ongoing results in TAXUS VI further demonstrate the margin of safety of the commercial slow- release TAXUS stent now implanted in more than four million patients worldwide," said Paul LaViolette, Boston Scientific Chief Operating Officer. "With no stent thrombosis after two years, a low cardiac death rate, and a low TLR rate, we continue to be impressed with how paclitaxel performs in this high-risk patient population."

"The four-year results from TAXUS VI demonstrate that the safety and efficacy benefits associated with the moderate-release TAXUS paclitaxel- eluting stent system were maintained in patients with complex coronary artery disease at four years," said Professor Grube. "The performance of the TAXUS stent in these patients was extremely impressive when considering the complexity of their disease, including patients with long lesions, small vessels, and those requiring multiple, overlapping stents."

The randomized, double-blind, co
'"/>




Page: 1 2 3

Related medicine technology :

1. New Study Suggests Better Patient Outcomes with CYPHER Sirolimus-Eluting Coronary Stent than with Taxus Stent in Real-World Clinical Settings
2. Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology
3. SPIRIT Clinical Data Reaffirm Strength of Taxus and Promus Drug-Eluting Coronary Stent Systems
4. Abbotts Xience V Everolimus Eluting Coronary Stent Superior to Taxus Stent in Spirit III U.S. Pivotal Clinical Trial
5. Genetic Analysis Systems Enter the Clinical Mainstream
6. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
7. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
8. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
9. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
10. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
11. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
Post Your Comments:
(Date:7/29/2015)... Company (NASDAQ: STAA ), a leading developer, manufacturer and ... today reported financial results for the second quarter ended July ... Net Sales of $18.7 Million Down 7% from the Prior ... from the Weakening Euro and Yen , ICL Units ... APAC Sales Down 1% Including Korea - Up 16% Excluding ...
(Date:7/29/2015)... (Vanda) (NASDAQ: VNDA ), today announced financial and ... 2015. "We are impressed with U.S. sales ... Polymeropoulos M.D., Vanda,s President and CEO, "further investments in ... set the stage for the next level of growth ... Total net product sales for the second quarter of ...
(Date:7/29/2015)... , July 29, 2015  Depomed, Inc. (NASDAQ: ... that its Board of Directors, after careful consideration ... and legal advisors, has unanimously rejected the purported ... Horizon Pharma plc (NASDAQ: HZNP ) ("Horizon") ... Depomed in an all-stock transaction (the "July 21 ...
Breaking Medicine Technology:STAAR Surgical Reports Second Quarter 2015 Results 2STAAR Surgical Reports Second Quarter 2015 Results 3STAAR Surgical Reports Second Quarter 2015 Results 4STAAR Surgical Reports Second Quarter 2015 Results 5STAAR Surgical Reports Second Quarter 2015 Results 6STAAR Surgical Reports Second Quarter 2015 Results 7STAAR Surgical Reports Second Quarter 2015 Results 8STAAR Surgical Reports Second Quarter 2015 Results 9STAAR Surgical Reports Second Quarter 2015 Results 10STAAR Surgical Reports Second Quarter 2015 Results 11STAAR Surgical Reports Second Quarter 2015 Results 12STAAR Surgical Reports Second Quarter 2015 Results 13STAAR Surgical Reports Second Quarter 2015 Results 14STAAR Surgical Reports Second Quarter 2015 Results 15STAAR Surgical Reports Second Quarter 2015 Results 16STAAR Surgical Reports Second Quarter 2015 Results 17STAAR Surgical Reports Second Quarter 2015 Results 18STAAR Surgical Reports Second Quarter 2015 Results 19STAAR Surgical Reports Second Quarter 2015 Results 20STAAR Surgical Reports Second Quarter 2015 Results 21STAAR Surgical Reports Second Quarter 2015 Results 22STAAR Surgical Reports Second Quarter 2015 Results 23STAAR Surgical Reports Second Quarter 2015 Results 24Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 2Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 3Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 4Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 5Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 6Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 7Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 8Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 9Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 10Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 11Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 12Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 13
... ROCKVILLE, Md., April 28 Stem cell company,Neuralstem, ... the European Patent,Office has granted Neuralstem a European ... of Stem Cells from,Embryonic and Adult Central Nervous ... in several European countries including France, Germany,Ireland, Spain, ...
... Data Show Significant Improvements With ROX-828 In Migraine Pain ... And Related Symptoms For Up to 48 Hours Vs. ... PHARMA, Inc. today,announced positive top-line data from a clinical ... the treatment of migraine,and related symptoms., The placebo-controlled ...
Cached Medicine Technology:Neuralstem Announces Issuance of Core Technology Patent in Europe 2ROXRO PHARMA Announces Positive Clinical Proof of Concept Results for Novel Intranasal Migraine Treatment 2ROXRO PHARMA Announces Positive Clinical Proof of Concept Results for Novel Intranasal Migraine Treatment 3
(Date:7/29/2015)... ... July 29, 2015 , ... In an effort to encourage ... of substance abuse that face today’s society, A Forever Recovery invited members of ... rehabilitation center. The facility, located in Southwest Michigan hosted a tour of the ...
(Date:7/29/2015)... ... July 29, 2015 , ... VideoLink , a ... Center, located in New York, NY, selected the ReadyCam on-site video studio to ... scientists to immediately access worldwide TV and cable news networks and participate in ...
(Date:7/29/2015)... ... 29, 2015 , ... Andrzej Klos, M.D., has been reviewed and approved as ... 38 years, is motivated each and every day by his sincere desire to help ... his many awards and accolades, which include multiple listings in many highly regarded medical ...
(Date:7/29/2015)... ... ... " Core Organizer ” was featured on NewsWatch as part of its monthly AppWatch, ... iOS, Android, and Windows. Joe Toohey, the host of AppWatch and technology expert, conducted ... organized. , Wouldn’t it be great if everyone could be a little more organized? ...
(Date:7/29/2015)... ... July 29, 2015 , ... The report “Atherosclerosis - ... Atherosclerosis is a slow, progressive disease that may start in childhood. The report ... best-in-class products. Complete report on Atherosclerosis Pipeline with 78 market data tables and ...
Breaking Medicine News(10 mins):Health News:MADD Victim Services Specialist Visits A Forever Recovery Rehabilitation Facility 2Health News:Columbia University Medical Center Installs a VideoLink ReadyCam® Video Studio on Campus; Medical Experts Able to Appear on Live TV at a Moment's Notice 2Health News:Columbia University Medical Center Installs a VideoLink ReadyCam® Video Studio on Campus; Medical Experts Able to Appear on Live TV at a Moment's Notice 3Health News:NJ Top Docs Presents, Dr. Andrzej Klos of Carepoint Health Pediatrics! 2Health News:NJ Top Docs Presents, Dr. Andrzej Klos of Carepoint Health Pediatrics! 3Health News:Get More Organized with the Core Organizer App 2Health News:Atherosclerosis Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com 2Health News:Atherosclerosis Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com 3Health News:Atherosclerosis Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com 4
... , , , , ... AUDIO: University of Michigan School of Public Health researcher Stoddard,s research shows ... more information. , , , , ... , , , , , , , ...
... Reporter , THURSDAY, June 2 (HealthDay News) -- Young ... suffer from anxiety, loneliness, low self-esteem and sadness, they ... scores, new research suggests. Children do not fall ... disruptive period before their parents divorce, the study revealed. ...
... Psychology researchers at the University of Alberta have found an ... gambling: People confronted with risky choices respond differently when they ... on the odds of winning or losing. , The ... a choice between a sure win versus a double-or-nothing win. ...
... Ga. Scientists may have a way to make ... and more effective against some cancers. The chemotherapeutic agent used ... results in kidney damage or failure in about 30 percent ... physicians can do today to protect the kidneys is advise ...
... By Steven Reinberg HealthDay Reporter , WEDNESDAY, ... be scary, but University of Michigan researchers offer some ... fallen substantially in recent years. Much of this ... in hospitals that do a lot of them and ...
... parents get divorced generally don,t experience detrimental setbacks in the ... upwhen it comes to math and interpersonal social skills after ... study. In addition, the study, which appears in the ... that children of divorce are more likely to struggle with ...
Cached Medicine News:Health News:People who have had head injuries report more violent behavior 2Health News:People who have had head injuries report more violent behavior 3Health News:People who have had head injuries report more violent behavior 4Health News:Divorce Can Hurt Kids' Math Scores, Friendships 2Health News:Divorce Can Hurt Kids' Math Scores, Friendships 3Health News:Cause and potential treatment found for cancer drug's kidney toxicity 2Health News:High-Risk Surgeries Getting Safer: Study 2Health News:High-Risk Surgeries Getting Safer: Study 3Health News:Study: Children of divorce lag behind peers in math and social skills 2
... the only four-color, automated benchtop flow cytometry ... cell sorting. Designed specifically to support a ... offers software instrument control, auto-sample loading, and ... productivity. FACSCalibur is fully modular so it ...
Multiparameter laser and arc lamp flow cytometer for all applications in immunology, microbiology, cell biology, pathology, hematology, lymphocyte dubset and cell analysis....
... Ultracompact high end desktop multilaser flow cytometer ... kind of cell analysis and absolute counting. ... and two different side scatter signals in ... The new CyFlow ML instrument can perform ...
This unique system combines the analytical power of a research cytometer into a compact, truly walk away, clinical analyzer ergonomically designed to expedite sample throughput....
Medicine Products: